The FY2025 (Dec) proxy of Viatris names 15 peer companies for pay. Among Viatris and these peers, CEO pay was 7th highest of 8 and total shareholder return was 7th highest of 8.
7th highest of 8in Viatris and its pay peers, FY2025 (Dec) by CEO pay:
$7.3M$28.4M
7th highest of 8in Viatris and its pay peers, FY2025 (Dec) by total shareholder return:
$80$255
Pay peer group, FY2025 (Dec) proxy
| Gilead Sciences | ||
| Pfizer | ||
| Amgen | ||
| Abbott Laboratories | ||
| Bristol Myers Squibb | ||
| Zoetis | ||
| Regeneron Pharmaceuticals | ||
| Bausch Health Companies Inc. | Not disclosed | Not disclosed |
| Baxter International | Not disclosed | Not disclosed |
| Biogen | Not disclosed | Not disclosed |
| Novartis AG | Not disclosed | Not disclosed |
| Organon & Co. | Not disclosed | Not disclosed |
| Sandoz | Not disclosed | Not disclosed |
| Sanofi S.A. | Not disclosed | Not disclosed |
| Teva Pharmaceutical Limited | Not disclosed | Not disclosed |
15 companies
PSU comparator group
The companies that relative total shareholder return is measured against for performance stock units.
| S&P 500 Pharmaceutical Index (index) | Not disclosed | Not disclosed |
1 company
Changes by year
FY2025 (Dec) proxy
- AddedSandozpay peer groupdue to its market capitalization and added Sandoz as a new member of the peer group
- RemovedEli Lilly & Copay peer groupdue to its market capitalization and added Sandoz as a new member of the peer group
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.